<DOC>
	<DOCNO>NCT02469415</DOCNO>
	<brief_summary>The goal clinical research study learn pacritinib , either alone combination azacitidine decitabine , help control MDS . The safety drug drug combination also study .</brief_summary>
	<brief_title>Pacritinib Patients With Lower-Risk Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description>Study Drug Administration : Each cycle 28 day . If find eligible take part study , take pacritinib mouth 2 time day Cycles 1-4 . Each dose 12 hour apart ( 1 dose morning , 1 dose even ) . After Cycle 4 , study doctor think best interest , may able continue take pacritinib combination either azacitidine decitabine . The study doctor tell drug receive . The study doctor tell drug receive . Decitabine azacitidine may administer local doctor MD Anderson . Cycle 1 Part 2 administer MD Anderson . Commercial supply decitabine azacitidine use . You receive either azacitidine vein 1 hour Days 1-5 Cycles 5 beyond decitabine vein 1 hour injection skin Days 1-7 Cycles 5 beyond . You return unused study drug and/or empty bottle study visit . Study Visits : One ( 1 ) time week Cycle 1 Day 1 cycle , blood ( 1½ teaspoon ) draw routine test . You may blood draw local lab clinic closer home , study doctor think acceptable . The result blood draw sent study doctor . On Day 28 ( +/- 5 day ) Cycles 1 4 , bone marrow aspiration/biopsy check genetic mutation cytogenetic testing . If begin receive pacritinib combination either azacitidine decitabine , also test repeat Cycle 4 combination therapy . On Day 1 Cycle 1 , Day 28 Cycles 1 4 , time doctor think need , EKG . Length Treatment : You may continue take pacritinib 4 cycle . If doctor think best interest , may eligible continue take study drug combination either azacitidine decitabine long doctor think best interest . You longer able take study drug ( ) disease get bad , intolerable side effect occur , unable follow study direction . Your participation study end-of-treatment visit . After end therapy and/or 30 day last dose study drug , study staff follow health status phone call every 2 month ( +/- 2 month ) receive another cancer treatment . End-of-Treatment Visit : About 28 day last dose study drug ( ) : - Blood ( 1½ teaspoon ) draw routine test . - If doctor think need , bone marrow aspirate/biopsy check status disease . This investigational study . Pacritinib FDA approve commercially available . It currently use research purpose . Azacitidine decitabine FDA approve commercially available treatment MDS . The study doctor explain study drug design work . Up 40 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<criteria>1 . Signed informed consent indicate patient aware investigational nature study , keep policy MDACC , must obtain prior study specific procedure . 2 . Patients histologically confirm diagnosis MDS World Health Organization ( WHO ) classification , lowerrisk MDS define IPSS classification ( Low Int1 disease ) RIPSS classification ( Very Low Low ) eligible . Patients MDS/MPD overlap syndrome include CMML also eligible Low Int1 disease per IPSS . Patients may receive MDSdirected therapy ( i.e . lenalidomide ) , although patient prior exposure hypomethylating agent ( e.g . 5azacitidine decitabine ) eligible . 3 . The interval prior treatment time study drug administration least 1 week ( except hydroxyurea steroid therapy ) recovery prior therapyrelated toxicity 4 . Age &gt; /= 18 year old . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . 6 . Adequate liver function , evidence serum bilirubin &lt; /= 2x laboratory normal range ( except patient Gilbert 's Disease ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; /= 2.5x upper limit normal ( ULN ) &lt; /= 5x ULN hepatic disease involvement present determine investigator . 7 . Serum creatinine ( Cr ) &lt; /= 2x ULN 24hour creatinine clearance &gt; /=50 ml/min 8 . Subjects reproductive potential must agree use acceptable contraceptive method duration time study 6 month completion treatment . Women childbearing potential must negative blood urine pregnancy test within 72 hour start treatment . 1 . Subjects prior exposure hypomethylating agent ( 5azacitidine decitabine ) exclude . 2 . Subjects prior exposure JAK2 inhibitor therapy ( i.e . ruxolitinib prior pacritinib therapy ) exclude . 3 . Any prior coexisting medical condition investigator 's judgment substantially increase risk associate subject 's participation study . 4 . Psychiatric disorder alter mental status preclude understand informed consent process and/or completion necessary study procedure . 5 . Active uncontrolled serious infection sepsis study enrollment . Patients receive antibiotic infection control may include study . 6 . Gastrointestinal disorder may significantly interfere absorption study drug . 7 . Subjects receive potent CYP3A inhibitor within 7 day prior initiation study treatment . 8 . History myocardial infarction , severe/unstable angina , symptomatic congestive heart failure ( New York Heart Failure ( NYHA ) Class III IV congestive heart failure ) within 6 month prior study enrollment LVEF &lt; 50 % 9 . Impaired cardiac function include ongoing cardiac dysrhythmias Grade &gt; 2 , ejection fraction &lt; 50 % , atrial fibrillation grade , QTc prolongation &gt; 450 m , factor increase risk QT prolongation ( i.e . family history long QT interval syndrome , hypokalemia define serum potassium &lt; 3.0 mEq/L ) 10 . Diagnosis malignancy within last 3 year curatively treat nonmelanoma skin cancer , carcinoma situ cervix , organconfined treat nonmetastatic prostate cancer , situ breast carcinoma complete surgical resection , superficial transitional cell bladder carcinoma . 11 . Known active Hepatitis A , B C. 12 . Known HIV seropositivity . 13 . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Lower-risk</keyword>
	<keyword>Pacritinib</keyword>
	<keyword>5-azacitidine</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-azacytidine</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
</DOC>